MX339451B - Composiciones y metodos para inmunoterapia. - Google Patents
Composiciones y metodos para inmunoterapia.Info
- Publication number
- MX339451B MX339451B MX2010010866A MX2010010866A MX339451B MX 339451 B MX339451 B MX 339451B MX 2010010866 A MX2010010866 A MX 2010010866A MX 2010010866 A MX2010010866 A MX 2010010866A MX 339451 B MX339451 B MX 339451B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- immunotherapeutics
- treatment
- proliferative disorders
- microbial infections
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 3
- 230000001413 cellular effect Effects 0.000 abstract 2
- 210000000987 immune system Anatomy 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000000813 microbial effect Effects 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 150000003935 benzaldehydes Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención proporciona nuevas composiciones y métodos inmunoterapéuticos útiles para tratar o prevenir infecciones microbianas, sistema inmune deficiente, enfermedades en las que las células se han vuelto obligadamente anaeróbicas y trastornos proliferativos celulares que incluyen el cáncer. Los inmunoterapéuticos de la presente usan derivados de benzaldehído, precursores e intermediarios, solos o en combinación con agentes terapéuticos adicionales para estimular el sistema inmune e inhibir la proliferación celular. Los inmunoterapéuticos de la presente invención son útiles, en particular, en el tratamiento de infecciones microbianas y trastornos proliferativos celulares que son resistentes a los métodos de tratamiento tradicionales como los antibióticos y la quimioterapia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4221008P | 2008-04-03 | 2008-04-03 | |
| PCT/US2009/002134 WO2009145841A1 (en) | 2008-04-03 | 2009-04-03 | Compositions and methods for immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2010010866A MX2010010866A (es) | 2011-02-24 |
| MX339451B true MX339451B (es) | 2016-05-27 |
Family
ID=41267359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010010866A MX339451B (es) | 2008-04-03 | 2009-04-03 | Composiciones y metodos para inmunoterapia. |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20090281047A1 (es) |
| EP (1) | EP2271350A4 (es) |
| JP (1) | JP2011516478A (es) |
| CN (1) | CN102046180A (es) |
| AU (1) | AU2009251848A1 (es) |
| CA (1) | CA2757437A1 (es) |
| IL (1) | IL208445A0 (es) |
| MX (1) | MX339451B (es) |
| NZ (1) | NZ588668A (es) |
| RU (1) | RU2010144744A (es) |
| WO (1) | WO2009145841A1 (es) |
| ZA (1) | ZA201007830B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
| BRPI0923164A2 (pt) | 2008-12-19 | 2016-01-26 | Graceway Pharmaceuticals Llc | formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica. |
| GEP20156418B (en) | 2009-07-13 | 2016-01-11 | Medicis Pharmaceutical Corp | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| EP3056201A1 (en) * | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
| US20130171279A1 (en) * | 2012-01-04 | 2013-07-04 | Physicianrx, Llc | Composition for Reducing Side- and After-Effects of Cancer Treatment |
| CN103156951A (zh) * | 2013-04-11 | 2013-06-19 | 太仓市胜舟生物技术有限公司 | 一种治疗b细胞淋巴瘤的组合药物 |
| WO2015107375A1 (es) * | 2013-12-20 | 2015-07-23 | Vergara Campillo Ramiro Moises | Combinación de piridoxina, ácido fólico y iones de magnesio para el tratamiento del cáncer |
| AU2017214668B2 (en) | 2016-02-04 | 2022-12-08 | Auransa, Inc. | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity |
| WO2018027029A1 (en) * | 2016-08-03 | 2018-02-08 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of fosaprepitant and aprepitant |
| WO2019032411A1 (en) * | 2017-08-07 | 2019-02-14 | Cognate 3 Llc | COMPOSITIONS AND METHODS FOR INDUCING APOPTOSIS IN ANAEROBIC CELLS AND ASSOCIATED CLINICAL METHODS FOR THE TREATMENT OF CANCER AND PATHOGENIC INFECTIONS |
| WO2022200833A1 (en) * | 2021-03-25 | 2022-09-29 | 2B-Shvat Ltd. | Benzaldehyde extracted from rosales as foodstuff preservative, animal-feed additive, and for treatment of the covid-19 virus |
| JP7018531B1 (ja) | 2021-04-30 | 2022-02-10 | 潤 齋藤 | Ａｘｌ阻害剤 |
| US20250161234A1 (en) * | 2022-02-24 | 2025-05-22 | Shmuel ROBINOV | Methods of use of benzaldehyde compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4882314A (en) * | 1985-12-02 | 1989-11-21 | Rikagaku Kenkyusho | A composition and method of treating selected malignant conditions |
| US6407071B1 (en) * | 1998-06-04 | 2002-06-18 | Co-Enzyme Technology Ltd. | Method and composition for treating malignant cells |
| NO309305B1 (no) * | 1999-02-19 | 2001-01-15 | Norsk Hydro As | Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater |
-
2009
- 2009-04-03 MX MX2010010866A patent/MX339451B/es active IP Right Grant
- 2009-04-03 WO PCT/US2009/002134 patent/WO2009145841A1/en not_active Ceased
- 2009-04-03 US US12/418,342 patent/US20090281047A1/en not_active Abandoned
- 2009-04-03 NZ NZ588668A patent/NZ588668A/xx not_active IP Right Cessation
- 2009-04-03 CA CA2757437A patent/CA2757437A1/en not_active Abandoned
- 2009-04-03 JP JP2011502995A patent/JP2011516478A/ja active Pending
- 2009-04-03 EP EP09755204A patent/EP2271350A4/en not_active Withdrawn
- 2009-04-03 AU AU2009251848A patent/AU2009251848A1/en not_active Abandoned
- 2009-04-03 CN CN2009801205538A patent/CN102046180A/zh active Pending
- 2009-04-03 RU RU2010144744/15A patent/RU2010144744A/ru not_active Application Discontinuation
-
2010
- 2010-10-03 IL IL208445A patent/IL208445A0/en unknown
- 2010-11-02 ZA ZA2010/07830A patent/ZA201007830B/en unknown
-
2011
- 2011-08-19 US US13/213,933 patent/US20110311477A1/en not_active Abandoned
- 2011-08-19 US US13/214,022 patent/US20110311478A1/en not_active Abandoned
- 2011-08-19 US US13/213,819 patent/US20110311476A1/en not_active Abandoned
-
2012
- 2012-06-17 US US13/525,317 patent/US20120251490A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110311478A1 (en) | 2011-12-22 |
| AU2009251848A1 (en) | 2009-12-03 |
| US20110311476A1 (en) | 2011-12-22 |
| CA2757437A1 (en) | 2009-12-03 |
| MX2010010866A (es) | 2011-02-24 |
| US20120251490A1 (en) | 2012-10-04 |
| WO2009145841A1 (en) | 2009-12-03 |
| CN102046180A (zh) | 2011-05-04 |
| US20090281047A1 (en) | 2009-11-12 |
| NZ588668A (en) | 2013-01-25 |
| ZA201007830B (en) | 2011-07-27 |
| US20110311477A1 (en) | 2011-12-22 |
| JP2011516478A (ja) | 2011-05-26 |
| EP2271350A1 (en) | 2011-01-12 |
| RU2010144744A (ru) | 2012-05-10 |
| EP2271350A4 (en) | 2011-05-18 |
| IL208445A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX339451B (es) | Composiciones y metodos para inmunoterapia. | |
| PH12013500299B1 (en) | Pyrrolopyrimidine compounds and uses thereof | |
| PH12015500186A1 (en) | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib | |
| MY171289A (en) | Inhibitors of e1 activating enzymes | |
| MX2009001309A (es) | Compuestos de heteroarilo utiles como inhibidores de enzimas de activacion e1. | |
| PH12012500497A1 (en) | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs | |
| WO2007033023A3 (en) | Compositions and methods for the diagnosis and therapy of bcl2-associated cancers | |
| WO2010003520A3 (en) | Anti-tumor immunotherapy | |
| SG179163A1 (en) | Novel tricyclic protein kinase modulators | |
| MX2009006627A (es) | Quinazolinas para la inhibicion de pdk1. | |
| NZ708928A (en) | Mannose derivatives for treating bacterial infections | |
| SG179161A1 (en) | Tricyclic compounds and pharmaceutical uses thereof | |
| MX2019007613A (es) | Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos. | |
| WO2010002779A3 (en) | Naphthyridininones as aurora kinase inhibitors | |
| WO2009114703A3 (en) | Combination therapy for the treatment of cancer | |
| MX344590B (es) | Inhibidores de f1f0-atpasas de tipo pirazolilguanidina y sus usos terapéuticos. | |
| MX2013006398A (es) | Inhibidores de f1f0-atpasas de tipo piridonilguanidina y usos terapeúticos. | |
| EP4199961A4 (en) | COMBINATION IMMUNOTHERAPY METHOD FOR TREATING CANCER | |
| HK1209639A1 (en) | Gpbp-1 inhibition and its therapeutic use | |
| WO2011056566A3 (en) | Compounds and methods for treatment of cancer | |
| WO2011153243A3 (en) | Anti-angiogenesis therapy for treating gastric cancer | |
| WO2012158933A3 (en) | Macrocycllc therapeutic agents and methods of treatment | |
| WO2008042435A3 (en) | Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same | |
| WO2011019636A3 (en) | Methods and compositions for the treatment of cancers and pathogenic infections | |
| WO2009126335A3 (en) | Ant2 inhibitor compounds and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |